Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · Real-Time Price · USD
3.750
+0.380 (11.28%)
At close: Dec 20, 2024, 4:00 PM
3.700
-0.050 (-1.33%)
After-hours: Dec 20, 2024, 7:59 PM EST
Checkpoint Therapeutics Revenue
Checkpoint Therapeutics had revenue of $47.00K in the twelve months ending September 30, 2024, down -72.51% year-over-year. In the year 2023, Checkpoint Therapeutics had annual revenue of $103.00K, down -46.35%.
Revenue (ttm)
$47.00K
Revenue Growth
-72.51%
P/S Ratio
n/a
Revenue / Employee
$2,043
Employees
23
Market Cap
183.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 103.00K | -89.00K | -46.35% |
Dec 31, 2022 | 192.00K | -76.00K | -28.36% |
Dec 31, 2021 | 268.00K | -801.00K | -74.93% |
Dec 31, 2020 | 1.07M | -639.00K | -37.41% |
Dec 31, 2019 | 1.71M | -1.80M | -51.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 304.34M |
Nutex Health | 292.00M |
InfuSystem Holdings | 132.78M |
Innate Pharma | 36.20M |
Cellectis | 36.04M |
TScan Therapeutics | 9.36M |
Lyell Immunopharma | 63.00K |
CKPT News
- 3 days ago - Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval - Seeking Alpha
- 8 days ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 5 weeks ago - Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date - Seeking Alpha
- 5 weeks ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 3 months ago - Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - GlobeNewsWire
- 3 months ago - Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success - Seeking Alpha
- 4 months ago - Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire